International: +1-347-960-6455
Rhinovirus Infection Therapeutics to Witness Significant Growth due to Positive Results in the Coming Years

According to a new research report Rhinovirus Infection Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, rhinovirus infection therapeutics currently exhibits a proliferating pipeline with 10 therapeutic candidates.

Insights into Rhinovirus Infection Therapeutics Pipeline

Rhinovirus infections, caused by rhinoviruses, occurs in the upper or lower respiratory tracts. The occurrence frequency of the infection is a year-around, but most often in spring and fall seasons. The infections are mostly acknowledged as ‘common cold’, but the infection can also lead to lesser degree pneumonia, sore throats, sinus infections, ear infections, and bronchiolitis. In children, around 8-10 course of occurrence have been observed during the first two-years. The symptoms manifest after the incubation period of viruses (12-24 hours) and last till 7-11 days. The signs and symptoms of the infection include nasal irritation or dryness, headache, less sense of smell and taste, hoarseness, cough, and fever.

Insights into Pipeline Segments

According to the research findings, most of the drug candidates are being developed as vaccine and administered by the intramuscular and intranasal route. The major advantage of vaccines includes they generate acquired immunity in the body against the rhinovirus infections. The building immunity by the vaccines resist the complications of infections.

Positive Results are Expected to Drive the Advancements in Rhinovirus Infection Therapeutics Pipeline

The companies developing therapeutics for the treatment of various infections due to rhinovirus, have shown positive clinical results in the various phases of drug development. For instance, in Pre-Clinical study, TVB-3567, showed positive results and minimized infections caused by rhinovirus, respiratory syntaxial virus, parainfluenza virus, severe adult respiratory syndrome virus, and hepatitis virus. The drug candidate reduced the replication of these viruses and helped in minimizing the number of inflammatory cells in the infected areas of the body. The drug candidate also prevented the emergence of drug resistance.

Browse Detailed Report on "Rhinovirus Infection Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:

Technological Advancements Play a Pivotal Role in the Rhinovirus Infection Therapeutics Pipeline Development

It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of rhinovirus infection therapeutics. These technologies play an important role in the drug development; thereby, helping the companies to develop more specific and effective targeted therapies. For instance, Immune Dampening and Refocusing Technology developed by Biological Mimetics Inc., demonstrated a high potential in designing vaccines by minimizing limitations in the vaccine’s development. The technology focuses on identifying the epitopes that stimulate non-protective, strain-specific, or disease-enhancing immunity. The immune-mapping in technology helps in the identification of structure of antigens. This immune-based technology designed antigens can be introduced into the viral vectors or their recombinants subunits.

Some of the key players involved in the development of rhinovirus infection therapeutics in the late and mid stage include Romark L.C., Johnson & Johnson, Istari Oncology Inc., Merck & Co. Inc., and Vaxart Inc.

Rhinovirus Infection Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises of detailed pipeline analysis of rhinovirus infection therapeutics, analyzing the emerging therapies and their progress status in different phases of development. Comprehensive insights into the pipeline phase products has been provided with special focus on strategic development activities inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, and patent. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to rhinovirus infection therapeutics.